Latest:
Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors
Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Alvaro Alencar, MD
Alvaro Alencar, MD, a hematologist/oncologist, an associate professor of clinical medicine, and associate chief medical officer in the Division of Hematology at the University of Miami Sylvester Comprehensive Cancer Center.
Latest:
Dr Alencar on the Ongoing Development of NX-5948 in CLL and B-Cell Malignancies
Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.
Andrea Visentin, MD
Andrea Visentin, MD, is , an oncologist in the Department of Medicine, Hematology Unit, at the University of Padova in Italy.
Latest:
Dr Visentin on the Relevance of Cost Analysis in Guiding Treatment Sequencing for CLL
Andrea Visentin, MD, discusses the relevance of cost analysis in guiding treatment sequencing for patients with chronic lymphocytic leukemia.
Núria Agustí, MD
Núria Agustí, MD, is a postdoctoral fellow at MD Anderson Cancer Center in Houston, Texas.
Latest:
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Núria Agustí, MD, discusses patient eligibility in a cohort study assessing adjuvant chemoradiotherapy vs radiotherapy alone in patients with cervical cancer.
Pedro C. Barata, MD, MSc, FACP
Latest:
Postimmunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies
Experts discuss key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib alone in inoperable advanced renal cell carcinoma (aRCC) after immune checkpoint inhibitor (ICI) treatment, along with insights from real-world data on sequencing strategies and the efficacy of tyrosine kinase inhibitors (TKIs) after prior ICI therapy.